Using rodent models of obesity and metabolic dysfunction, the research group demonstrated that the triple-agonist approach produced meaningful reductions in body weight and improved glycaemic parameters compared to both placebo and comparator compounds targeting fewer receptors
storage is governed by the IMP label, the sponsor's Pharmacy Manual, and GCP guidelines, with the trial site pharmacist as the definitive authority
While some who take them may only see trivial reductions in weight, the majority will see substantial change, with the average weight loss ranging from 14-20% of initial body weight
But, from the data we have so far, it seems that they will be similar to those of Wegovy and Mounjaro
You still have full access to Zepbound and Wegovy if you choose through our traditional GLP-1 program Our intake questionnaire and consultation with a provider determine if you medically qualify Our GLP-1 ID programs are structured based on the duration you select at checkout
The clinical evidence behind GLP-1 active compounds as a class is substantial, drawn from large, controlled trials of FDA-approved formulations